The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 22, 2025
Filed:
Dec. 15, 2020
Merck Sharp & Dohme Llc, Rahway, NJ (US);
Msd International Gmbh (Singapore Branch), Singapore, SG;
Agency for Science, Technology and Research, Singapore, SG;
Nicolas C. Boyer, Somerville, MA (US);
Michael B. Garrigou, Newton, MA (US);
Sookhee Nicole Ha, Lewisville, TX (US);
Chunhui Huang, Arlington, MA (US);
Anthony W. Partridge, Cambridge, MA (US);
Tomi K. Sawyer, Southborough, MA (US);
Pietro Aronica, Singapore, SG;
Charles W. Johannes, Singapore, SG;
Srinivasaraghavan Kannan, Singapore, SG;
Chandra S. Verma, Singapore, SG;
Tsz Ying Yuen, Singapore, SG;
Nicolas C. Boyer, Somerville, MA (US);
Michael B. Garrigou, Newton, MA (US);
Sookhee Nicole Ha, Lewisville, TX (US);
Chunhui Huang, Arlington, MA (US);
Anthony W. Partridge, Cambridge, MA (US);
Tomi K. Sawyer, Southborough, MA (US);
Pietro Aronica, Singapore, SG;
Charles W. Johannes, Singapore, SG;
Srinivasaraghavan Kannan, Singapore, SG;
Chandra S. Verma, Singapore, SG;
Tsz Ying Yuen, Singapore, SG;
Merck Sharp & Dohme LLC, Rahway, NJ (US);
MSD International GMBH (Singapore Branch), Singapore, SG;
Agency for Science, Technology and Research, Singapore, SG;
Abstract
The invention provides compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein the variables are as described herein. The compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (K-Ras) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.